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Abstract
A highly sensitive, automated, purely add-on, high-throughput pseudovirion-based neutralization assay (HT-PBNA) with
excellent repeatability and run-to-run reproducibility was developed for human papillomavirus types (HPV) 16, 18, 31, 45,
52, 58 and bovine papillomavirus type 1. Preparation of 384 well assay plates with serially diluted sera and the actual cell-
based assay are separated in time, therefore batches of up to one hundred assay plates can be processed sequentially. A
mean coefficient of variation (CV) of 13% was obtained for anti-HPV 16 and HPV 18 titers for a standard serum tested in a
total of 58 repeats on individual plates in seven independent runs. Natural antibody response was analyzed in 35 sera from
patients with HPV 16 DNA positive cervical intraepithelial neoplasia grade 2+ lesions. The new HT-PBNA is based on Gaussia
luciferase with increased sensitivity compared to the previously described manual PBNA (manPBNA) based on secreted
alkaline phosphatase as reporter. Titers obtained with HT-PBNA were generally higher than titers obtained with the
manPBNA. A good linear correlation (R2 = 0.7) was found between HT-PBNA titers and anti-HPV 16 L1 antibody-levels
determined by a Luminex bead-based GST-capture assay for these 35 sera and a Kappa-value of 0.72, with only 3 discordant
sera in the low titer range. In addition to natural low titer antibody responses the high sensitivity of the HT-PBNA also allows
detection of cross-neutralizing antibodies induced by commercial HPV L1-vaccines and experimental L2-vaccines. When
analyzing the WHO international standards for HPV 16 and 18 we determined an analytical sensitivity of 0.864 and
1.105 mIU, respectively.
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Introduction
Human papillomaviruses (HPV) are causally involved in the
induction of cervical cancer and its precursor lesions. Currently,
12 HPV types are classified as carcinogenic to humans and an
additional 8 types as probably or possibly carcinogenic to human
[1]. Worldwide, the ten HPV types identified most frequently in
cervical cancer are HPV 16, 18, 33, 45, 31, 58, 52, 35, 59 and 56
[2]. HPV infection is recognized as an absolute requirement for
the transformation process in cervical cancer [3,4], but host cell
cofactors also play a role. Built on the recognition of the HPV
causality in cervical cancer development, two commercial
vaccines, GardasilH and CervarixH targeting the two most
prevalent carcinogenic HPV types 16 and 18 were licensed in
the EU in 2006 and 2007, respectively [5,6]. Both vaccines employ
the major capsid protein L1 in form of virus-like particles (VLPs)
as antigen and are highly effective in preventing infections by HPV
types 16 and 18 as well as cervical intraepithelial neoplasias
induced by these viruses [7,8].
The mode of action of both vaccines is considered to be the
induction of neutralizing antibodies directed against L1 surface
loops of the viral capsid. With more than six years history on
papillomavirus prophylactic vaccination, monitoring long term
development of protective titers of neutralizing antibodies is of
increasing importance. Thus, there is a need for the evaluation of
such antibody responses, specifically for functional assays analyz-
ing neutralizing antibodies.
Papillomaviruses cannot be replicated in simple cell culture
systems. Therefore, in the past a number of functional assays have
been developed to measure antibody-mediated neutralization of
papillomaviruses. These assays involved the use of authentic
viruses [9] [10] and so called pseudovirions with an encapsidated
reporter construct [11,12,13]. In addition, neutralizing antibodies
have been measured more indirectly e.g. by a hemagglutination
inhibition assay [14] or by competition of binding of a neutralizing
monoclonal antibody [15].
The current ‘gold standard’ for measuring neutralizing anti-
HPV antibodies is a manually performed pseudovirion-based
neutralization assay (manPBNA; [16]) using secreted alkaline
phosphatase (SEAP) as reporter. Although infectious pseudovirions
of different PV types can be easily produced, the manPBNA
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remains tedious and variable, restricting its applicability mainly to
small sample numbers.
Several arguments make a case for the need of a high-
throughput neutralization assay with improved sensitivity: (i)
requirement of larger serum sample numbers for follow-up studies
on current vaccines, (ii) detection of cross-neutralizing antibodies
induced by the commercial vaccines, and (iii) monitoring the effect
of simplified vaccination schemes. Also, induction of neutralizing
antibodies by second generation vaccines, e.g. based on the L2
protein needs to be assessed. Finally, large scale neutralization
assays would allow addressing questions on naturally occurring
protective immunity against HPV infections. Especially in respect
to antibody responses against natural papillomavirus infections
there are high demands for sensitivity and reproducibility in a
neutralization assay. To date, high-throughput detection of HPV
capsid-specific antibodies has been possible only with the aid of
surrogate detection assays such as ELISA and competitive
Luminex immunoassay (cLIA) using VLPs as antigen. Here we
describe the adaptation of the PBNA to a high-throughput (HT)
setting. We developed a purely add-on system in which the serial
dilution of serum samples is separated from the cell-based assay,
providing a high degree of flexibility. The high-throughput assay
demonstrates high robustness with little intra- and inter-assay day
variability. Also, the HT-PBNA shows higher sensitivity compared
to the manually performed assay using SEAP as reporter. In its
current format, the neutralization titer of 110 serum samples for
seven HPV types can be determined in a single run. The HT-
PBNA will allow the execution of large studies on vaccine- and
naturally-induced immunity against HPV infections.
Materials and Methods
Human Sera
Base line sera from 35 women with HPV 16 mono-infected high
grade cervical intraepithelial neoplasia (CIN 2/3) participating in
a vaccination trial with chimeric HPV 16 L1-E7 virus-like particles
[17] were used as examples of naturally acquired HPV 16
antibodies. For vaccine-induced HPV 16 antibodies, 72 post-
vaccination sera of this vaccination trial were used. Ethics
statement [17]: From December 2000 until May 2002, 39
patients were enrolled into the study at 10 German study sites
(Berlin, Duesseldorf, Hamburg, Hanover, Jena, Mainz, Munich
(2), Muenster, Rostock). Positive votes were obtained from each
internal review board of the participating centers. Ethics
regulations were coordinated by the ‘Ethik-Kommission der
Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät’
(http://www.ethikkommission.uniklinikum-jena.de/
Ethik_Kommission+der+FSU+Jena+.html). All investigations in-
volving humans have been performed in accordance with the
principles embodied in the Declaration of Helsinki. The study was
performed in compliance with the guidelines of Good Clinical
Practice as described in the International Conference on
Harmonization of Good Clinical Practices guidelines step 4
(1996). All patients signed an informed consent form. Study
participation took 24 weeks with 2 optional follow-up visits after 36
and 48 weeks. Blood samples were collected at baseline, 2 weeks
after each vaccination and after 24 weeks. Peripheral blood
mononuclear cells (PBL) and plasma were stored frozen until
analysis.
A post-vaccination serum collected after obtaining written
informed consent from a 21 years old female volunteer 3 years post
completion of a 3-dose Gardasil vaccination course was used as
positive standard on all assay plates. Approval for obtaining and
testing this serum derives from ‘Ethik-Kommission der Bayer-
ischen Landesärztekammer’, Munich, Germany.
HPV Pseudovirion Preparation
Pseudovirions (PSV) were prepared as previously described
[18,19] with some modifications. Pseudovirions were prepared by
co-transfecting 293TT cells with plasmids encoding humanized
HPV L1 and L2 genes. For HPV 16 we used a bi-cistronic L1 and
L2 expression construct, exceeding packagable size. For Produc-
tion of HPV 18 and BPV 1 PSV we used two plasmids encoding
L1 and L2 separately. As a reporter we used a plasmid encoding
the enzyme Gaussia luciferase or a plasmid encoding secreted
human placental alkaline phosphatase (SEAP). Co-transfection
was performed on 46106 293TT cells using TurboFect (Fermen-
tas) according to the manufacturer’s instructions with minor
modifications. Briefly, 10–15 mg DNA were mixed with 2 volumes
of TurboFect and 1 ml of unsupplemented DMEM and added to
293TT cells which were subsequently incubated at 37uC, 5%CO2
for 72 hours. Absence of cell culture contaminations and
authentication of the cell line were determined by the Multiplex
cell Contamination Test [20] and a SNP-based human cell line
authentication test as described [21].
For pseudovirion extraction, 293TT cells were harvested and
the cell pellet was resuspended in an equal volume of lysis buffer.
Lysis buffer was prepared by adding 58,3 ml of 10% Brij58 (w/v)
(Sigma) and 6,6 ml RNAse A/T (Fermentas) to every ml of DBPS
(Invitrogen). Cells were rotated overnight at 37uC to induce
pseudovirion maturation. On the next day, salt extraction was
performed by adding 0,17 volumes of 5 M NaCl, followed by the
addition of 250 units of benzonase for 1 h at 37uC. The
pseudovirions were purified by Optiprep gradient and fractions
were stored at 280uC.
manPBNA
The SEAP manPBNA was essentially performed as described
[16]. As target cells 293TT cells were seeded at a concentration of
15,000 cells per well on 96-well plates in DMEM (Sigma),
supplemented with 10% FCS (Gibco, BRL), 1% penicillin/
streptomycin (Life Technologies) and 125 mg/ml hygromycin
(Roche). The following day, the pseudovirions were diluted in
DMEM (1:5000) and mixed with the sera at different dilutions.
After 15 min incubation at room temperature, the medium of the
293TT cells was replaced by 200 ml of the pseudovirion solution.
The following controls were included: untreated cells, cells treated
with pseudovirions alone, and cells treated with pseudovirions in
the presence of neutralizing monoclonal antibodies. Detection of
SEAP in the cell culture supernatant was performed five days later
with the chemiluminescent SEAP Reporter Gene Assay (Roche)
according to the manufacturer’s instructions. All sera were tested
in duplicates. The neutralization activity was calculated using the
following formula: % neutralization= (Psvalone2Psvserum)/(Psvalo-
ne2PsvAb)*100%. Sera with at least 70% neutralizing activity were
regarded as neutralizing.
Luminex GST-L1 Capture Serology
Antibodies binding to HPV L1 proteins were measured in a
multiplexed glutathione S-transferase capture immunosorbent
assay with fluorescent bead-based Luminex technology as previ-
ously described in detail [22,23] [24,25]. The cut off for the
Luminex assay was calculated from the reactivity of pre-vaccine
sera that were negative at 1:100 dilution (,109 MFI). At the
1:2700 dilution that was used to measure MFI-values in a linear
range for the vaccine sera, the maximum reactivity of the above
Papillomavirus Neutralization Assay
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mentioned negative pre-vaccine sera was 10 MFI and therefore
used as cut off value for the sera at 1:2700 dilution.
Reporter Cell Line HeLaT for HT-PBNA
The 293TT cells originally described as target cell line for the
PBNA were not suited for the add-on assay layout for the HT-
PBNA since attachment of the 293TT cells to the assay plates was
very variable and resulted in high assay variability. Therefore, we
generated a HeLa cell line stably transfected with a linearized
expression construct for the SV 40 large T-antigen. HeLa cells
(tested for absence of contaminations and for authenticity as
described above [20]) were transfected and then cultivated under
selection using hygromycin B. Several single clones were isolated
and tested for transduction by HPV 16 pseudovirions. One clone
(HeLaT clone-4) was subsequently used in all assays.
High-throughput Pseudovirion-based Neutralization
Assay (HT-PBNA)
A. Assay plate preparation. In the automated high-
throughput set up all sample racks and plates were barcoded to
ensure continuous sample and data tracking with the help of
pipetting robots and plate readers equipped with barcode readers.
Sera were transferred from a 96 well storage in SBS standard
format (http://www.slas.org/community/microplate_standards.
cfm) to columns 3 and 13 of 384 well intermediate plates
(polypropylene V-bottom plates, Greiner; figure 1) using a Perkin
Elmer MPII 4-tip automated liquid handling robot and then 10-
fold serially diluted with an EP3 robot (384 channel head) in
DMEM cell culture medium (Invitrogen) supplemented with 10%
fetal calf serum (Gibco) and Penicillin/Streptomycin (Life
Technologies). Starting from the initial dilution in column 3 the
sera were transferred from column n to column n+1 containing
cell culture medium and the solution mixed after each transfer on
a Variomag Teleshake (Inheco, Germany) for 45 sec at 1300 rpm.
The initial dilution, transferred and provided volumes depend
on the desired starting concentration, the step width of the serial
dilution and the number of replicates that have to be prepared
from the serial dilution. Sera from the vaccination trial with
chimeric HPV 16 L1-E7 virus-like particles were diluted in 3-fold
increments starting from 1/5 (18 ml serum +72 ml medium) to 1/
157,464 and finally 5 ml of the serial dilutions were transferred
with the EP3 robot to each of nine assay plates (white 384 well cell
culture plates, PerkinElmer). The plates were sealed immediately
with a polypropylene cover foil (HJ-Bioanalytik, Germany) and
stored at 220uC.
B. Assay assembly and read out. Assay plates containing
the serum dilutions were equilibrated to room temperature (RT),
centrifuged for 1 min at 1.0006g and the cover foil was removed
before 15 ml PSV diluted in fully supplemented cell culture
Figure 1. HT-PBNA protocol. Assay plate preparation (A) and neutralization assay (B) are separated. In a first step, serial dilutions of serum samples
are performed on one dilution plate. Identical assay plates are generated by transferring the dilutions to multiple replica-assay plates which can be
stored at 220uC. In the second step, the neutralization assay is carried out in a add-on format using the previously prepared assay plates. A) Assay
plate preparation. Sera are transferred from a 96 well storage in SBS standard to a 384 well polypropylene V-bottom plate for serial dilution with a
pipetting robot in cell culture medium. Finally the serially diluted sera are transferred with the same pipetting robot to each of 3*n white 384 well cell
culture assay plates (n =number of PV-types). The plates are sealed immediately with a cover foil and stored at 220uC until their use in the PBNA. B)
Assay assembly and read out. Assay plates are thawed and pseudovirions followed by reporter cells are added with a bulk dispenser. Three
identical assay plates originating from the same serum dilution plate are used for each PV- type. After 2 days of incubation the luminescence from the
Gaussia reporter is read directly in the assay plates. Inhibition (%) is calculated by normalization of the luminescence to the mean of the negative
control wells without serum present on each plate. The median of the triplicate values is used for the calculation of the ED50-value (effective dilution
giving 50% inhibition) for each serum according to the four parameter logistic curve fit model y =A+(B2A)/(1+(C/x)‘D).
doi:10.1371/journal.pone.0075677.g001
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medium were added with a FlexDrop bulk dispenser (PerkinEl-
mer) and incubated for 1 h at RT (Figure 1). Thereafter 20 ml
HeLaT cells were added with the FlexDrop dispenser to give a
density of 1500 cells/well and incubated for 2 days in a cell
incubator at 37uC/5% CO2. The plates where then removed from
the incubator and equilibrated to RT before 20 ml/well glow
substrate solution (PJK, Germany) for the Gaussia luciferase was
added with the FlexDrop dispenser. Luminescence was read
directly in the assay plates after 11 min in an Envision plate reader
(PerkinElmer) equipped with stacker and internal barcode reader.
Three identical assay plates originating from the same serum
dilution plate were used for each PSV- type. Inhibition (%) was
calculated by normalization of the luminescence in serum-dilution
containing wells to the mean of the negative control wells without
serum present on each plate. The median of the triplicate values
was used for the calculation of the ED50-value (effective dilution
giving 50% inhibition) for each serum according to the four
parameter logistic curve fit model: y =A+(B2A)/(1+(C/x)‘D)
(model 205 from the functions available in XE-Designer, IDBS,
United Kingdom).
Plasmids and cell lines are available on request for non-
commercial users following standard material transfer agreement.
Results
In order to translate the (manual) PBNA to high-throughput
format we first identified, then optimized and standardized critical
parameters of the assay including pseudovirion (PSV) concentra-
tion, serum-PSV incubation time, cell lines and cell density.
Effect of Cell Type and Density on Reporter Signal
In preceding experiments we tested different cell lines in the
HT-PBNA. The 293TT cell line [13] appeared ill-suited for the
add-on assay layout of the HT-PBNA, where trypsin-treated cells
are added to premixed PSV and sera. 293TT cell attachment to
the assay plates was highly variable and relatively slow (.4 hours
for .90% cell attachment) causing a significant delay in reporter
gene expression. In contrast, more than 90% of cells of a newly
established HeLa subline (HeLaT clone-4) stably expressing the
SV40 large T-antigen were found to attach within 1 hour of
seeding (data not shown). With the HT-PBNA protocol, a range of
500–3000 HeLaT clone-4 cells per well in the 384-well assay
plates showed little influence on the intensity of the Gaussia
luciferase signal (Figure 2). The luminescence signal in an
ATPlite1stepTM assay (Perkin Elmer) is directly correlated with
cell number/metabolic activity and was proportional to the
number of seeded cells, up to 2500 cells/well when confluency
was reached after 2 days of incubation. In all subsequent assays,
1500 cells/well were used to ensure that cell density is not
exceeding sub-confluency. The robustness of the PBNA towards
variations in cell number is crucial for the application in a 384 well
format where ‘‘edge effects’’ of the outer most wells often influence
cell growth.
Typically, for the luminescence signal of the Gaussia luciferase
reporter assay in 384 well plates we observed a coefficient of
variation (CV) of less than 3% within rows and less than 6% for
the whole plate (data not shown). The higher CV for the whole
plate is mainly a consequence of the decay of the Gaussia
luciferase luminescence during the time that is necessary to read
the 384 well plate (75 sec), even when employing a glow substrate
with reduced turnover rates. The luminescence reader measures
the plate row-wise so that the decrease in signal is negligible within
a row. Sera are diluted within a row and therefore the effect of a
decreasing luminescence signal on the calculation of the ED50 is
minimal and no correction for position effects is necessary.
Pseudovirion Concentration
PSV preparations of the same or different papillomavirus
types can vary considerably in regard to particle concentration,
L1 capsid protein to reporter plasmid ratio and transduction
activity. A standardization of PSV preparations by L1 or
plasmid concentration is therefore not the best indicator of assay
performance. Titration of PSV preparations in the HT-PBNA
demonstrated significant variation (Figure 3). At high PSV
concentrations signals were frequently reduced. All PSV
preparations reached similar maximal intensities but the
dilutions giving maximal luminescence signal spanned a wide
range even for PSV preparations of the same HPV type (e.g.
HPV 16 PSV in Figure 3). To investigate the effect of PSV
dilution on sensitivity and variability of the PBNA we
determined the effective PSV dilution yielding 50% neutraliza-
tion (ED50) of a serum derived from a Gardasil-immunized
individual for different dilutions of HPV 16 and HPV 18 PSV
(Figure 4). As expected, lowering the PSV concentrations raised
the ED50 values indicating an increasing analytical sensitivity. At
low PSV concentrations the ED50 reached a plateau. The
maximal gain in sensitivity was typically 3-fold relative to the
highest PSV concentrations. However, the variability of the
ED50 determination markedly increased with lower PSV
concentrations, indicating reduced assay robustness. Therefore,
PSV concentrations slightly lower than those generating
maximal luminescence intensity were considered to represent
the best compromise between low variability and high analytical
sensitivity and were used in all future HT-PBNA.
Pre-incubation Time of PSV and Sera
In the manPBNA described by Pastrana et al., sera and PSV
are pre-incubated in a separate plate for 1 hour to ensure
complete antibody binding before adding the mix to pre-plated,
attached reporter cells. In contrast, for the add-on HT-PBNA
trypsin-treated reporter cells are added as a suspension to a
mixture of PSV and serum in the cell culture assay plates. To
investigate the effect of incubation time of the PSV/serum-
Figure 2. Influence of cell density on Gaussia luciferase activity.
HeLaT clone 4 cells were seeded at the indicated densities into white
384 well plates containing HPV 16 PSV. After incubation at 37uC for 2
days substrate for the Gaussia luciferase or ATPLite1stepTM was added
and the luminescence measured. Columns show the median lumines-
cence of 64 wells with bars indicating the standard deviation.
doi:10.1371/journal.pone.0075677.g002
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premix on the ED50-value in the HT-PBNA, our standard
serum from a GardasilH immunized individual was pre-
incubated for 2–120 minutes with HPV 16 or HPV 18
pseudovirions before the reporter cells were added. Notably,
we found little effect of the PSV-serum pre-incubation time on
the ED50-value (Figure 5). For all incubation times investigated
ED50-values did not differ significantly for both HPV 16 and
HPV 18 PSVs. This indicates that uptake of the PSV by the
added reporter cells is sufficiently slow to allow for antibody
binding and neutralization irrespective of incubation time. In
the automated HT-PBNA we used a standard pre-incubation
time of 1 hour which allows the handling of larger batches of
assay plates under identical conditions.
Effect of High Serum Concentration
At a dilution of 1:20 we observed that most human sera yielded
60–90% inhibition of bovine papillomavirus 1 (BPV-1) PSV
activity in the HT-PBNA, irrespective of whether the sera
originated from HPV-vaccinated or non-vaccinated persons. In
addition, at a 1:20 dilution, these sera also neutralized PSV of all
other tested HPV types. This effect was not due to reduced
viability of the reporter cell line as high serum concentrations
rather stimulated cell growth (data not shown). Pastrana and
colleagues observed a similar ‘‘cross-species inhibition’’ at 1:20
dilution for some sera in their SEAP PBNA [16] and consistent
with their report, we were also not able to eliminate the inhibition
of BPV PSV by heat inactivation, freeze-thaw cycles or
centrifugation of the sera. At a dilution of $1:40 none of the
sera inhibited BPV PSV activity and sera from vaccinated persons
specifically neutralized PSV from vaccine-HPV types or closely
related HPV-types only. We therefore conclude that this low titer
inhibition is non-specific and not due to cross-neutralizing
antibodies.
Reproducibility of Titers Determined by PBNA
The reproducibility of titers obtained with the HT-PBNA for
HPV 16 and HPV 18 was determined with our serum standard
tested a total of 58 times on individual plates in seven
independent runs over a period of two months in the course
of a larger serological study (Figure 6). A mean coefficient of
variation (CV) of 13% was obtained for the ED50-values of 58
repeats with both, the HPV 16 and HPV 18 HT-PBNA. The
CV for the intra-run variability with 8–10 repeats per run
ranged from 6 to 12%. For a cell-based assay, these CV
indicate a low variability. As the underlying assay is newly
Figure 3. Titration of different PSV preparations. Serial dilution of PSV preparations from HPV types 16, 18, 31, 45, 52, 58 and BPV-1 were
assayed for Gaussia luciferase activity in the HT-PBNA. For HPV types 16 and 18 a second PSV preparation is indicated by an asterisk (*). Luminescence
signals are expressed as relative light units (RLU). The titers for undiluted HPV 16, 18, and BPV-1 PSV were 3.06109, 3.96109, 1.161010 genomes per
ml, respectively.
doi:10.1371/journal.pone.0075677.g003
Figure 4. Influence of PSV concentration on HT-PBNA analytical sensitivity and robustness. Neutralization titers of a serum from a
GardasilH immunized individual expressed as ED50 values (open circles and open squares) with the variability (bars indicating the 95% confidence
intervals) were determined at different PSV concentrations. The maximal luminescence intensities (RLU) obtained without serum are shown as
crosses. An arrow indicates the dilution of the PSV preparation that was used in subsequent neutralization assays.
doi:10.1371/journal.pone.0075677.g004
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developed, no data on reproducibility in other laboratories are
yet available.
Assay Application: Detection of Neutralizing Antibodies
Derived from Natural Infection
Previously, we analyzed a total of 1271 sera from a different
vaccine trial (25% pre-vaccination sera; data not shown) for
neutralization of HPV 16, HPV 18 and BPV 1 PSV in the HT-
PBNA and found only 8 sera (0.6%) with a BPV 1-specific
ED50.80 (maximal BPV-specific ED50 was 120). Considering the
neutralization of BPV 1 in the PBNA as unspecific we defined an
ED50 of 80 as the cut off value to classify sera positive in the
neutralization assay for all HPV types.
First, to determine the PV type-specific detection of antibodies
in our PBNA we tested the WHO international standards for
antibodies to HPV 16 [26] and HPV 18 [27] using PSV of HPV
types 16, 18, 31, 45, 52, 58 and BPV 1. The HPV 16 standard
neutralized specifically HPV 16 in the HT-PBNA with an ED50 of
463 (Figure 7), which is at least five times higher than the titers
obtained with the manPBNA in five laboratories participating in
the collaborative study to assess the suitability of the serum as an
International Standard for antibodies to HPV 16 in immunoassays
and pseudovirion neutralization assays [26]. With an assigned
potency of 10 mIU/ml for the WHO standard after reconstitution
as directed in 0.5 ml distilled water, the neutralization titer of 463
in the HT-PBNA would correspond to an analytical sensitivity of
0.864 mIU. The HPV 18 standard neutralized specifically HPV
18 in the HT-PBNA with an ED50 of 579 (Figure 7) correspond-
ing to an analytical sensitivity of 1.105 mIU.
To compare manPBNA with the HT-PBNA, we tested sera
from a German HPV 16 L1-E7 chimeric virus-like particles
vaccination trial in CIN patients [17] for neutralization of HPV
16 PSV. In addition, data previously obtained with a Luminex-
based total IgG-assay using GST-L1 as an antigen were available
for these sera. Thirty-six patients with HPV 16 DNA-positive,
high-grade cervical intraepithelial neoplasia (CIN) in groups of 12
participants had received a high- or low-dose vaccine or placebo at
weeks 0, 2 and 4. A total of 107 analyzed sera included 35 base
line (pre-vaccination) sera and 24 post-vaccination sera each from
week 2, 4 and 14 of the study.
First, we investigated the performance of the HT-PBNA in
detecting neutralizing antibodies as a result of natural infection
with 35 available pre-vaccine serum samples using PSVs from
HPV types 16, 18, and 31 (Figure 8). All patients from the trial had
CIN2+ lesions and were HPV 16 DNA positive at the time of
enrollment.
Figure 5. Effect of PSV-serum premix incubation time on neutralization titer. A serum from a GardasilH vaccinated individual was pre-
incubated for different times with HPV 16 or HPV 18 PSVs before the neutralization assay was initiated by the addition of reporter cells. ED50 values
with 95% confidence intervals are shown.
doi:10.1371/journal.pone.0075677.g005
Figure 6. HT-PBNA inter- and intra-run variability of neutralization titers. The ED50 values for HPV 16 and HPV 18 PSV of the serum
standard were determined in 58 repeats on seven assay days (runs) over a period of 2 months. For six of the 7 assay days, triplicates of the standard
serum dilutions were assayed 8 times each, for one assay date the standard serum was assayed 10 times.
doi:10.1371/journal.pone.0075677.g006
Papillomavirus Neutralization Assay
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Using an ED50 of 80 as cut-off, among the 35 sera tested, 29
(83%), 6 (17%) and 8 (23%) were found positive for neutralization
of HPV 16, HPV 18 and HPV 31 PSV, respectively (Figure 8).
The geometric mean titer (GMT) of all sera was 449 (GMT of
positive sera: 723), 59 (123) and 69 (299) for HPV 16, HPV 18 and
HPV 31, respectively. All HPV 18 and HPV 31 neutralizing sera
were also positive in the HPV 16 HT-PBNA, with the exception of
one serum that was only positive for HPV 18 (ED50 = 111). The
HPV 31 DNA status of the patients has not been determined, but
the well-documented cross-reactivity of HPV 16 antibodies against
HPV 31 might explain neutralization of HPV 31. These HPV
types are closely related and induction of cross-protection against
HPV 31 has been demonstrated by the two commercial HPV-
vaccines containing HPV 16 virus-like particles [28]. Interestingly,
two sera neutralized HPV 31 PSVs with a 3-fold higher titer
compared to HPV 16 PSVs, which highly indicates that the
antibodies might be derived from an infection with HPV 31.
In general there is a direct, linear correlation between the titers
determined in HT-PBNA and manPBNA based on using SEAP,
especially for the vaccine-induced high titer sera (Figure 9B).
However, the HT-PBNA yields titers about 10-fold higher than
the manPBNA (Figures 9A and 9B). In the subgroup of the 35 pre-
vaccination sera that contain only antibodies from natural
infection, 20 sera were non-neutralizing in the manPBNA. These
20 sera comprise all 6 sera that were negative in the HT-PBNA
but also 14 HT-PBNA positive sera with an ED50 GMT of 258
and a maximal ED50 of 1703. All 15 manPBNA positive sera
(GMT (ED50) = 250) were also positive in the HT-PBNA (GMT
(ED50) = 1895). This indicates a higher sensitivity of the HT-
PBNA in the detection of sera with low neutralization titers.
The HT-PBNA also showed a good agreement with a Luminex-
based total IgG-assay using GST-HPV 16 L1 as antigen
(Figure 9C). An R2-value of 0.7 (0.67 for the 29 HT-PBNA
positive sera only) was determined for the linear regression analysis
between GST-HPV 16 L1 antibody reactivity (expressed as
median fluorescence intensity, MFI) and the HT-PBNA ED50
values. Of the 35 sera, 28 (80%) were considered HPV 16
seropositive by the GST-HPV 16 L1 antibody binding assay
(reactivity .109 MFI) and 29 (83%) sera neutralization antibody
positive by the HT-PBNA (ED50.80). A Cohen’s kappa
coefficient of 0.72 indicated good agreement between these two
assays.
Analysis of Post-vaccine Sera
For the 72 analyzed post-vaccination sera of the trial, covering a
very wide range of titers, a direct correlation of the manPBNA and
the HT-PBNA was observed, but again the HT-PBNA yielded
approximately 10 fold higher titers (figure 9B). All except two of
the post-vaccination sera were positive in both assays. These two
sera were negative in the manPBNA and had low titers in the HT-
PBNA with ED50-values of 135 and 204, respectively.
As for the low titer pre-vaccine sera, the HT-PBNA and the
Luminex-based total IgG-assay showed a good correlation with a
R2 of 0.61 for the linear regression (Figure 9D). All 72 sera were
positive in both assays applying an ED50 of 80 as cut off for the
HT-PBNA and 10 MFI for the HPV 16 L1 antibody binding
assay. Some sera with relative low reactivity in the Luminex assay
compared to the HT-PBNA were most probably caused by
handling issues in the Luminex experiment as they had high
reactivity in both PBNAs.
Detection of L1 and L2 Vaccine-induced Neutralization
Activity Against 7 Papillomavirus Types
An important application of PBNA, ‘the gold standard in vitro
assay’, for assessing the protective potential of vaccine-induced
antibodies, is the detection of cross-neutralization activity against
non-vaccine HPV types. The high sensitivity of our HT-PBNA
Figure 7. Analytical sensitivity and type-specificity of the HPV 16 and HPV 18 HT-PBNA. Titration of the WHO International Standards for
antibodies to HPV 16 (left) and HPV 18 (right) in HT-PBNA using PSV of HPV types 16, 18, 31, 45, 52, 58 and BPV-1.
doi:10.1371/journal.pone.0075677.g007
Figure 8. Detection of neutralizing antibodies as result of
natural infection by HT-PBNA. Thirty-five pre-vaccination sera from
a study involving patients with CIN2+ lesions were tested for
neutralizing antibodies against PSVs of HPV types 16, 18 and 31. The
geometrical mean titer for each HPV type is indicated as a horizontal
line and the cut off value (ED50 = 80) as a dashed line.
doi:10.1371/journal.pone.0075677.g008
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allows the detection of cross-protective antibodies induced by
commercial L1-based vaccines as shown in Figure 10A for our in-
house standard serum, a collected from a 21 year old female
volunteer 3 years after completion of a 3-dose GardasilH
vaccination. The ED50 of this serum for HPV 16, 18, 31 and 58
was 19308, 1952, 111 and 205, respectively. No neutralization of
HPV types 45 and 52 or BPV-1 PSV was observed.
In Figure 10B the reactivity of a high titer CervarixH serum in
the HT-PBNA is shown. In addition to the vaccine-types 16 and
18 with titers .30,000 also cross-neutralization activity against the
non-vaccine HPV types 31, 45, 52 and 58 with ED50-values of
2842, 230, 86 and 95, respectively, was detected.
As the PSV are composed of L1 and L2 it is also possible to
measure neutralizing antibodies directed against the minor capsid
protein L2. In Figure 10C the titration of an experimental serum
from a mouse immunized with HPV 16 and HPV 31 L2 (aa 17–
36) inserted in the capsid of adeno-associated virus 2 (AAV2) [29]
in the HT-PBNA is shown. In addition to the vaccine type HPV
16 PSVs of HPV 18, 45, 58 and BPV are also neutralized by the
serum with ED50- values of 1796, 179, 289, 149 and 109,
respectively. HPV 31 and HPV 58 however, escape this
neutralization.
Discussion
Neutralizing antibodies directed against the L1 major capsid
protein play a key role in vaccine-induced immunity against HPV
but very likely also in natural immunity. In the past two decades a
number of assay systems have been developed and applied to
Figure 9. Comparison of HPV 16 HT-PBNA (Gaussia) with manPBNA (SEAP and Gaussia) and GST-HPV 16 L1 antibody binding assay
for natural and vaccine-induced HPV16-specific responses. HPV 16 HT-PBNA (A–D), manPBNA using SEAP reporter (A and B; titers, ED50) and
a bead-based GST-HPV 16 L1 antibody binding assay (C and D; median fluorescent intensity (MFI) at 1:100 or 1:2700 serum dilution) were used to
determine reactivity of pre- (n = 35; A and C) and post-vaccination (n = 72; B and D) sera. Serum samples analyzed were from women with HPV 16
positive, high-grade cervical intraepithelial neoplasia (base-line sera of the chimeric HPV 16 L1-E7 vaccination trial). Cut off values used for positive/
negative classification (broken lines in C) were an ED50 of 80 for the HT-PBNA and 109 MFI at 1:100 for the GST-L1 antibody binding assay.
doi:10.1371/journal.pone.0075677.g009
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detect L1-specific antibodies. Only some of these assays are able to
determine functionality of the antibodies in respect to neutraliza-
tion of HPV virions. Some of the functional assays include
challenge of animals or are so complex that they cannot be applied
for routine testing. Because high-throughput assays directly
measuring anti-HPV neutralizing antibodies were lacking, surro-
gate assays such as direct enzyme-linked immunosorbent assays
(ELISA) and competitive immunoassays with VLPs as antigen
were used [30,31]. In fact, to date all larger serological-
epidemiological and vaccine-monitoring studies have been carried
out with non-functional binding assays to monitor anti-L1
responses [32,33,34,35].
There is good reason to believe that anti-L1 antibodies are the
key mediators in providing vaccine-induced protection. First, these
antibodies have been detected in serum and genital secretion of
individuals vaccinated with Gardasil or Cervarix [36]. Next,
passive transfer of polyclonal serum and monoclonal antibodies is
sufficient to provide protection in mouse and dog challenge models
[37,38]. Finally, the observation that vaccine induced protection is
highly HPV type-specific is well in line with the fact that
neutralizing antibodies recognize L1 loop structures on the surface
of virus capsids and these structures are highly variable among
different PV types. In contrast, the remainder of the L1 protein is
highly conserved making it very difficult to explain the observed
type-specificity if T-cell responses were contributing significantly to
protection.
In 2004, Pastrana and colleagues described an in vitro
pseudovirion-based assay that allowed detection of neutralizing
antibodies and this assay is currently considered the gold standard
for assaying protective anti-L1 response [16]. It should be noted,
however, that to date a formal proof of in vitro detection of
neutralizing antibodies as a correlate for clinical protection is still
missing. The PBNA described by Pastrana et al. quantitatively
detects neutralizing antibodies against a number of different HPV
types, but the assay is laborious thereby limiting its use in respect
to the number of samples, replicates, titration steps and
papillomavirus types. To our knowledge the largest study to date
has been reported by Dessy et al. [39] in which manPBNA was
compared to ELISA and competitive ELISA.
In general, there is a good correlation between non-functional
and functional detection of anti-L1 responses when analyzing sera
from vaccinees. However, this correlation is the result of (a) the
specific induction of conformation-specific antibodies using well-
structured antigens with (b) a detection system monitoring
antibodies against properly folded antigens. Still, non-functional
assays tend to measure a higher degree of cross-type reactivity.
Previously, we demonstrated that a second generation L2
vaccine induces high titers of L2-binding antibodies but only a
fraction of these are neutralizing [40]. Detection of functional
antibodies will also be required when evaluating cross-protective
responses, either against closely related PV types or against
naturally occurring variants of the same type.
Figure 10. Titration of vaccine sera in the HT-PBNA using PSV of HPV types 16, 18, 31, 45, 52, 58 and BPV-1. A) Standard serum from
GardasilH vaccinated person. B) CervarixH vaccine serum. C) Serum from a mouse immunized with L2 epitopes (amino acids 17–36) from HPV16
inserted in the capsid of adeno-associated virus 2 particles.
doi:10.1371/journal.pone.0075677.g010
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To fulfill the need for an assay able to detect functional, i.e.
neutralizing antibodies, we modified the assay originally described
by Pastrana and colleagues. To establish the pseudovirion-based
neutralization assayin a high throughput setting, the protocol
should be as simple as possible while at the same time sensitivity
and reproducibility should be as high as possible. A key parameter
for increasing the throughput of our HT-PBNA was the separation
of assay plate preparation and performance of the neutralization
assay itself. Large batches of 384-well assay plates with serially
diluted serum samples can be prepared in advance by automated
liquid handling and subsequently stored at 220uC. After thawing,
all reagents for the succeeding steps are added consecutively with a
bulk dispenser to the assay plates in a pure add-on process, without
the requirement for removal of supernatants or pre-incubation on
separate plates. With the luciferase from Gaussia princeps it was
possible to quantify reporter expression with high sensitivity
directly in the cell culture plate with high absolute signals and
excellent signal to background ratios. Adding the substrate for
Gaussia princeps luciferase directly to the cell culture plate also
avoids the tedious transfer of small volumes of cell culture
supernatants to separate luminescence plates, an error-prone step
often introducing variation between replicate samples. The
compatibility of HT-PBNA with a 384 well format and bulk
dispension not only reduces reagent consumption and costs
generated by tip dispensing but also accelerates assay assembly
and throughput. Furthermore, a high throughput 384 well format
is preferable to a manual 96 well format when testing many
different pseudovirion types and sera as required, for example, in
L2 cross-protection analyses.
Neutralization titers of sera were determined from full titration
curves as effective dilutions giving 50% inhibition (ED50). Our
standard layout included 10 titration steps, which can be 2-fold, 3-
fold or 4-fold. By this, a large range of serum reactivity can be
captured, and even high titer immune sera will be fully titrated, a
prerequisite for accurate curve fitting. At the same time activity in
low titer sera is still determined. To ensure high data quality the
curve fit was performed from the median inhibition of triplicates
on identical replicates of assay plates. Barcoding of plates enabled
complete sample tracking and automated data evaluation with
specialized data calculation and management software such as
ActivityBase (IDBS).
While we observed a good correlation of HT-PBNA with
manPBNA and GST-L1 Luminex assays, the HT-PBNA showed a
significant higher sensitivity compared to the manPBNA originally
described by Pastrana et al, which uses SEAP as reporter system.
Of note, performing the neutralization assay manually but
following the protocol for the HT-PBNA we also reached higher
sensitivity indicating that the automated processing is not the
prime parameter for sensitivity. Still, automation leads to an
increase in robustness and decrease in assay variation which itself
allows the analysis of low reactive sera. While sensitivity in
detecting vaccine-type-specific neutralizing antibodies in vaccinees
at early time points after vaccination might not be a critical issue, it
becomes very important when analyzing either antibody titers in
long-term follow-up studies, natural immunity or vaccine induced
cross-protection against non-vaccine HPV types. For example the
cross-neutralization induced by GardasilH and CervarixH against
HPV types 31, 33 and 45 would probably have been missed using
the conventional manPBNA. Thus, HT-PBNA delivers more
sensitive and therefore comprehensive analyses of natural and
vaccine-derived immunity.
As a proof of concept, we demonstrated that HT-PBNA is
suitable for detection of L2-directed neutralizing antibodies. As
discussed above, functional assays are critical for L2 immunity due
to the discrepancy of non-functional and functional assays for this
antigen. Recently, Day et al. presented a modified in vitro
neutralization assay (L2-assay) with a much higher sensitivity for
L2 but not for L1-specific antibodies [41]. In this assay,
pseudovirions are first bound to extracellular matrix on assay
plates to induce structural rearrangements in the capsid. Subse-
quently, L2 is cleaved by addition of furin convertase followed by
transduction of cells devoid of heparan-sulfate proteoglycan. These
cells can only be infected by pseudovirions that have already been
cleaved by furin. In their study, Day and colleagues report 100–
200 fold higher L2-specific neutralizing antibody titers compared
to the standard assay while sensitivity for L1-specific neutralization
is not changed significantly. We did not perform comparison of
HT-PBNA and manPBNA sensitivity, although we wanted to
confirm that the altered protocol for HT-PBNA is compatible with
detection of L2 antibodies. Clearly, even if we assume that HT-
PBNA shows also higher sensitivity of detection of L2 antibodies,
in the same order of magnitude as we observed for the L1 antibody
detection we still are not able to reach the high sensitivity of the
L2-assay described by Day et al. or the in vivo challenge model
described by Roberts et al. [42]. The different incubation steps of
this modified L2 assay cannot be readily integrated into the high
throughput add-on assay system. Alternatively, Roden and
colleagues recently reported that production of pseudovirions in
cells overexpressing furin convertase generates pre-cleaved L2
pseudovirions serving as targets for sensitive L2-neutralizing
antibody detection (28th International Papillomavirus Conference,
Puerto Rico, 2012). These pseudovirions might be very well suited
for HT-PBNA, but it remains to be determined whether these
modified pseudovirions can be produced for different HPV types.
In conclusion, we present a protocol for a mostly automated
high throughput pseudovirion-based assay for the detection of
papillomavirus neutralizing antibodies. The increased sensitivity
and reproducibility will allow the design of large, comprehensive
studies for evaluating natural and vaccine-induced immunity.
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